Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report

Yang, Fusheng; Liu, Jie; Jiang, Yu

doi:10.3389/fendo.2022.810747

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests a potential for enhanced effectiveness of immunotherapy-based treatments within this subgroup. Case reports have illustrated positive responses and clinical benefits with immunotherapy in patients diagnosed with BC-Mp ( 47 – 50 ). In the present study, one patient received pembrolizumab with chemotherapy within a clinical trial, achieving a PFS of 20 months (the longest in the cohort) and an OS of 21 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience

Püsküllüoğlu,

Swiderska,

Konieczna

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Metaplastic breast cancer (BC-Mp), which includes a range of epithelial and mixed epithelial-mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC-Mp focuses mainly on retrospective data for radically treated patients. Notably absent are studies dedicated to the palliative treatment of BC-Mp with distant metastases. The present retrospective study investigated treatment modalities and prognosis in a multi-centre cohort of 31 female participants diagnosed with distant metastatic BC-Mp, including 7 patients with de novo metastatic disease. The median age of the patients was 61 years (range, 33–87 years), with 38.7% presenting local lymph node involvement. Lungs were the most common site for the metastatic disease (61.3%). Median Ki-67 index was 50% (range, 35–70%), and 80.7% of cases were classified as grade 3. Human epidermal growth factor receptor 2 (HER2) + and estrogen receptor + were detected in 12.9 and 6.5% of cases, respectively. A total of 62.4% of patients received first-line palliative systemic treatment. The 1- and 2-year overall survival (OS) were 38.5 and 19.2%, respectively. Receiving ≥1 line of palliative treatment was significantly associated with improved OS (P<0.001). Factors such as age, Ki-67 index, HER2 or hormonal status, presence of specific epithelial or mesenchymal components, location of metastases or chemotherapy regimen type did not influence OS. The present study provided insights into the clinicopathological profile, systemic treatment experience, prognostic factors and OS data of BC-Mp with distant metastases, emphasizing the imperative for clinical trials in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The trial specifically targets patients with HER2 − mBC-Mp with alterations in PIK3CA and PTEN. There are also a single report of successful applications of combined anti-angiogenic agent and immune check-point inhibitor ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience

Püsküllüoğlu,

Swiderska,

Konieczna

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Encouragingly, several case reports have demonstrated a remarkably durable response to IO with and without CT in the metastatic setting and pCR in the early setting [36][37][38][39][40] (Table 1). A case series published in 2021 showed that three out of five patients with metastatic MpBC responded to ICIs, of which one had mixed metaplastic squamous carcinoma with invasive lobular carcinoma and low ER expression, which achieved complete response [41].…”

Section: Discussionmentioning

confidence: 99%

Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature

Al-Awadhi,

Alnaqbi,

Albawardi

2024

Cureus

View full text Add to dashboard Cite

Metaplastic breast cancer (MpBC) is a rare form of breast cancer known for suboptimal response to chemotherapy, high recurrence rate, poor prognosis, and limited treatment options. Recent studies have reported that MpBC has high expression of programmed death ligand 1 and tumor-infiltrating lymphocytes, indicating the potential effectiveness of immunotherapy (IO) in MpBC. In addition, several reports have demonstrated the activity of IO in MpBC. In this case report, we present a case of recurrent MpBC that achieved durable, rapid, complete remission with atezolizumab (anti-PD-L1) and nab-paclitaxel with a continued response even after discontinued therapy.

show abstract

“…Recently, a patient affected by advanced metaplastic BC not responsive to standard adjuvant chemotherapy partially responded to the immunotherapeutic TORIPALIMAB combined with the angiogenesis inhibitor ANLOTINIB [ 154 ].…”

Section: Effect Of Antiangiogenic Agents Combined With Immune Checkpo...mentioning

confidence: 99%

The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies

Melaiu

Vanni

Portarena

et al. 2023

IJMS

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have a modest clinical activity when administered as monotherapy against breast cancer (BC), the most common malignancy in women. Novel combinatorial strategies are currently being investigated to overcome resistance to ICIs and promote antitumor immune responses in a greater proportion of BC patients. Recent studies have shown that the BC abnormal vasculature is associated with immune suppression in patients, and hampers both drug delivery and immune effector cell trafficking to tumor nests. Thus, strategies directed at normalizing (i.e., at remodeling and stabilizing) the immature, abnormal tumor vessels are receiving much attention. In particular, the combination of ICIs with tumor vessel normalizing agents is thought to hold great promise for the treatment of BC patients. Indeed, a compelling body of evidence indicates that the addition of low doses of antiangiogenic drugs to ICIs substantially improves antitumor immunity. In this review, we outline the impact that the reciprocal interactions occurring between tumor angiogenesis and immune cells have on the immune evasion and clinical progression of BC. In addition, we overview preclinical and clinical studies that are presently evaluating the therapeutic effectiveness of combining ICIs with antiangiogenic drugs in BC patients.

show abstract

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report

Cited by 5 publications

References 33 publications

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience

Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature

The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies

Contact Info

Product

Resources

About